WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

WilmerHale Counsels Accent Therapeutics in $40M Series A Financing

Firm News

Related Solutions

Helping clients launch their businesses and transform their innovative ideas into successful companies.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Comprehensive counseling for healthcare providers, insurers and the companies that supply them with products and services.

On May 18, 2018, Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, announced its $40M Series A financing to establish a discovery platform and pipeline of therapeutic candidates targeting RNA-modifying proteins, a novel target space for precision cancer therapies. The Column Group, Atlas Venture and EcoR1 Capital provided the investment.

The WilmerHale team advising Accent was led by Stuart Falber and included Jenna Ventorino and Alex Civetta.

Read Accent Therapeutics' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel